Companies

Public company developing enrichment processes for high-value stable isotopes used in advanced materials and related markets.

Focus: Stable isotope enrichment pathways for quantum, semiconductor, medical, and industrial materials.

ASP Isotopes subsidiary focused on nuclear fuel-cycle pathways, including uranium conversion work, HALEU-oriented enrichment efforts, and lithium isotope separation.

Focus: Uranium conversion, advanced enrichment pathways, and lithium isotopes.

Note: Fuel-cycle company under the ASP Isotopes group, not a medical radiopharma manufacturer.

Australian public company developing laser isotope separation technology across enrichment pathways.

Focus: Laser isotope separation technology development.

U.S. enrichment company central to domestic High-Assay Low-Enriched Uranium capacity and broader nuclear fuel enrichment infrastructure.

Focus: Uranium enrichment and HALEU production capacity.

Note: Key public reference point in the U.S. enrichment rebuild.

Major commercial uranium enricher with centrifuge plants in Europe and the United States.

Focus: Industrial uranium enrichment capacity.

Fuel-cycle company with major commercial enrichment capacity and broader nuclear services.

Focus: Enrichment and nuclear fuel-cycle operations.

U.S. uranium conversion joint venture context tied to UF6 feedstock supply ahead of enrichment.

Focus: Uranium conversion to enrichment feedstock.

Nuclear manufacturing company with roles across naval nuclear, commercial nuclear components, and selected isotope-related production activities.

Focus: Nuclear manufacturing and specialty isotope-linked capacity.

Nuclear fuel and technology company active across fuel fabrication and related nuclear systems.

Focus: Nuclear fuel systems and advanced fuel-cycle support.

Nuclear technology company developing pressurized water reactor methods for cobalt-60 production in partnership with source manufacturers. Extends Co-60 production beyond traditional CANDU routes into the broader PWR fleet.

Focus: PWR-compatible Co-60 production technology and deployment with utility partners for domestic and scalable supply.

Note: Important for the industrial isotope layer. Moves Co-60 production into reactor types that dominate the global power fleet.

Established supplier of isotope products, components, and related systems for medical and industrial users.

Focus: Commercial isotope products and radiopharmaceutical support systems.

Major provider of cyclotron and radiopharma production systems used in medical isotope infrastructure worldwide.

Focus: Cyclotrons and radiopharmaceutical production infrastructure.

Major Chinese isotope and radiation company involved in production and radiopharmaceutical-related supply.

Focus: Isotope production and radiation applications at scale.

Major pharmaceutical company with radioligand therapy programs that depend on reliable therapeutic isotope supply.

Focus: Radioligand therapeutics and clinical nuclear medicine platforms.

Pharmaceutical company with targeted radiotherapy products in the nuclear medicine landscape.

Focus: Targeted radiotherapeutic products and related clinical platforms.

Commercial nuclear medicine company active in diagnostic imaging agents and therapeutic development.

Focus: Diagnostic and therapeutic radiopharmaceutical products.

Radiopharmaceutical company developing diagnostic and therapeutic agents across oncology and related indications.

Focus: Targeted radiopharmaceutical diagnostics and therapy.

Large nuclear medicine manufacturer and supplier supporting diagnostic and therapeutic isotope products.

Focus: Medical isotope manufacturing and radiopharmaceutical supply.

European radiopharmaceutical and isotope company focused on targeted radionuclide therapy and related production capability.

Focus: Therapeutic radioisotopes and theranostic development.

U.S. company developing alternative production routes for molybdenum-99 and related medical isotope supply technology.

Focus: Mo-99 production technology and medical isotope manufacturing systems.

Company developing alternative production systems for medical isotopes and related nuclear technology applications.

Focus: Alternative medical isotope production technology.

Accelerator-based isotope production company building capacity for medical and related radioisotopes.

Focus: Accelerator production platforms for radioisotopes.

Expanding actinium-225 supply for targeted alpha therapy, including a large cGMP manufacturing project in Philadelphia intended to raise capacity once online.

Focus: Ac-225 production scale-up for advanced cancer therapies.

Note: Planned capacity expansion. Not the same as TerraPower's reactor business.

Company focused on actinium-225 production scale-up for targeted alpha therapy supply.

Focus: Ac-225 production capacity.

Accelerator-based medical isotope company active in actinium-225 and related radioisotope pathways.

Focus: Accelerator production of medical radioisotopes.

Major nuclear medicine and theranostics supply actor. Its Center for Theranostics Advancement supports commercial-scale radiopharmaceutical production and distribution, including actinium-225 related capacity growth.

Focus: Radiopharmaceutical manufacturing, theranostics supply, and last-mile nuclear medicine logistics.

Note: Important to the Ac-225 and broader therapeutic isotope commercial chain, especially where production volume and distribution meet.

Orano's nuclear medicine arm focused on targeted alpha therapy and related isotope development.

Focus: Targeted alpha therapy isotope platforms.

Radiopharmaceutical and isotope company active in therapeutic isotope development and supply.

Focus: Therapeutic radioisotope products.

Radiopharma company connected to PET manufacturing and broader nuclear medicine supply activity.

Focus: PET radiopharmaceutical manufacturing.

Technology company focused on cyclotron-based production routes for medical isotopes.

Focus: Cyclotron production technology for medical isotopes.

Major commercial processor and supplier in the cobalt-60 chain. Finished Co-60 sources for sterilization and selected medical uses depend on upstream power-reactor irradiation plus specialized source fabrication and distribution.

Focus: Co-60 supply for medical device sterilization, industrial irradiation, and related medical applications, tied to power-reactor production partners.

Note: Concentration point in the Co-60 network. Power-reactor harvest capacity and source processing both matter.

Belgian radioisotope producer important to global molybdenum-99 and related medical isotope supply.

Focus: Reactor-linked medical radioisotope production.

South African radioisotope producer linked to SAFARI-1 production pathways.

Focus: Medical radioisotope production and supply.

Australian nuclear science organization with reactor-based radioisotope production through OPAL-related pathways.

Focus: National radioisotope production and nuclear science services.

Operator context around the Petten research reactor and related irradiation services important to European isotope supply.

Focus: Research reactor irradiation and isotope-related services.

Polish radioisotope producer linked to MARIA reactor pathways.

Focus: National radioisotope production and supply.

Argentine nuclear technology company connected to research reactor and isotope infrastructure development.

Focus: Research reactor technology and related nuclear infrastructure.

Korea Atomic Energy Research Institute context around HANARO and national nuclear research capacity.

Focus: National nuclear research and irradiation capability.

Russian isotope trading and supply organization connected to national production capacity.

Focus: Isotope supply organization linked to domestic production nodes.

U.S. program coordinating isotope production and distribution across national laboratory capabilities.

Focus: Strategic research and specialty isotope availability.

Note: Infrastructure network rather than a single commercial producer.